Articles from Fellow Health

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological Association (AUA) 2025 meeting, taking place April 26–29 in Las Vegas. The studies highlight mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, announced today the publication of a study titled “Tissue of origin characterization of cell free DNA in seminal plasma: Implications for new liquid biopsies” in PLOS One. The research shows that seminal plasma is a rich source of cell free DNA (cfDNA) from somatic cells and provides new insights into its potential as a liquid biopsy for several conditions.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the findings of a study demonstrating the effectiveness of its mail-in postvasectomy semen analysis (PVSA) kits. The research, published in the Journal of Urology, found that Fellow Health’s mail-in testing significantly improves compliance rates, addressing longstanding challenges in verifying vasectomy success.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, recently achieved a significant milestone of delivering more than 100,000 patient test results since its product launch in 2020, highlighting its power to provide accurate and user-friendly testing for the male reproductive system.